Global Interventional oncology Market will reach $1.51 Billion by 2025: Meticulous Research®

Interventional oncology Market by Procedure [Embolization (TARE, TACE), Ablation (Thermal Ablation (Microwave, RF Ablation))], Product [Embolization (SIR-Spheres, TheraSpheres)], Application (Liver, Lung, Breast), and End User - Global Forecast to 2025.

pune, India - January 15, 2020 /MarketersMedia/ —

Technological innovations and advancements in image guided therapies are transforming the face of clinical practice over the past few years tremendously. This has brought interventional oncology from the phase of skepticism to fully accepted and preferred treatment technique, thereby fueling the growth of the global interventional oncology market. The increasing demand for non-invasive treatment procedures, growing awareness of the benefits of the minimally invasive procedures, and faster recovery times associated with such procedures are the major aspects garnering attention and preferences for
interventional oncology in tumor treatment. Meticulous Research® in its latest publication on Interventional Oncology Market states that this market will increase at a CAGR of 7.7% from 2019 to 2025 to reach $1,506.3 million by 2025.

To provide efficient analysis, Meticulous Research® has segmented this market on the basis of Procedure {Embolization (TARE, TACE, Bland Embolization), Ablation [Thermal Ablation (Microwave, RF Ablation, Cryoablation, others) Non-thermal Ablation]}, by Product {Embolization [Radioemblic Agents (SIR-Spheres, TheraSpheres, QuiremSpheres), Non-radioactive embolic agents (Microspheres, Drug-eluting beads, Particles)] Ablation (Generators, Consumables & Accessories)}, Application (liver, lung, breast), End user (Hospitals, ambulatory care center), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa).

Geographically, North America commanded the largest share in this market followed by Europe. The major share of North America is mainly attributed to the presence of well-established healthcare facilities, such as hospitals and ambulatory surgery centers in the region, greater adoption of advanced technologies, high level of awareness and spending towards healthcare services, and greater penetration of health insurance coverage in the region.

Get FREE Sample Copy of Interventional Oncology Market Report at:
https://www.meticulousresearch.com/request-sample-report/cp_id=4951

In terms of procedure, tumor embolization procedure segment accounted for the largest share in the global interventional oncology market in 2018. The large share of this segment is mainly due to better results with the procedure, specific targeting of tumor cells, and continuous advancements in embolization procedures and associated agents.

The two interventional oncology procedures — embolization and ablation — on the basis of products are segmented into tumor embolization (radioactive embolic agents/radioembolic agents and non-radioactive embolic agents) and tumor ablation (generators and consumables & accessories). Owing to being localized and directed radiation approach and favorable reimbursement scenario for radioembolization procedures, radioactive embolic agents segment commanded the largest share of global interventional oncology market in 2018.

Interventional oncology Market Key players:
The report provides competitive intelligence in terms of financials, growth strategies, product portfolios, and geographical presence for some of the key players in this market including Boston Scientific Corporation (U.S.), Cook Medical LLC (U.S.), C. R. Bard, Inc. (U.S.), Profound Medical Corp. (Canada), AngioDynamics, Inc. (U.S.), BTG plc (U.K.), Terumo Corporation (Japan), Medtronic plc (Ireland), HealthTronics, Inc. (U.S.), EDAP TMS S.A. (France), Neuwave Medical, Inc. (U.S.), Sirtex Medical Limited (Australia), Trod Medical (Belgium), Teleflex Incorporated (U.S.), Sanarus Technologies Inc. (U.S.), IMBiotechnologies Ltd. (Canada), MedWaves, Inc. (U.S.), and IceCure Medical Ltd. (Israel).

Asia-Pacific: The fastest growing regional market
North America commanded the largest share of the global interventional oncology market in 2018, followed by Europe, Asia-Pacific, Latin America, and Middle East & Africa. However, Asia-Pacific will be the fastest growing regional market due to accelerated economic growth of many countries in this region and growing government focus on healthcare sector. In addition, government initiatives towards the development of healthcare facilities, rising incidence & prevalence of cancer; rising awareness towards overall health and treatment availability; growing number of middle class population and their level of disposable income; increasing health insurance penetration; and growing aging population in the region are the key factors propelling the growth of the Asia-Pacific interventional oncology market.

Browse Full Research Report with TOC at:
https://www.meticulousresearch.com/product/Interventional-Oncology-Market-4951/

Table of Contents
1. Introduction
1.1. Market Ecosystem
1.2. Currency and Limitations
1.2.1. Currency
1.2.2. Limitations
1.3. Key Stakeholders

2. Research Methodology
2.1. Secondary Research
2.2. Primary Research

3. Executive Summary

4. Market insights
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Growing Preference for Minimally invasive Treatment Procedures
4.2.1.2. Increasing Incidence & Prevalence of Cancer
4.2.1.3. Rising Number of Hospitals
4.2.1.4. Technological Advancements in the Field of Radiology
4.2.2. Restraints
4.2.2.1. Potential Risks Associated with Interventional Oncology Procedures
4.2.2.2. High Cost Associated with Interventional Oncology Procedures
4.2.2.3. Paucity of Skilled Healthcare Professionals
4.2.3. Opportunities
4.2.3.1. Significant Growth Opportunities from Emerging Asian and Latin American Markets
4.2.3.2. Introduction of Cloud-Based Medical Imaging
4.2.4. Trend
4.2.4.1. Growing Integration of Image-Guided Solutions with Interventional Oncology Procedures

5. Interventional Oncology Market, by Procedure
5.1. Introduction
5.2. Tumor Embolization
5.2.1. Transarterial Radioembolization (TARE)
5.2.2. Transarterial Chemoembolization (TACE)
5.2.3. Bland Embolization
5.3. Tumor Ablation
5.3.1. Thermal Ablation
5.3.1.1. Radiofrequency Ablation (RFA)
5.3.1.2. Microwave Ablation (MWA)
5.3.1.3. Cryoablation
5.3.1.4. Other Thermal Ablation Procedures
5.3.2. Non-Thermal Ablation

6. Interventional Oncology Market, by Product
6.1. Introduction
6.2. Tumor Embolization
6.2.1. Radioembolic Agents
6.2.1.1. Sir-Spheres
6.2.1.2. TheraSphere
6.2.1.3. QuiremSpheres
6.2.2. Non-Radioactive Embolic Agents
6.2.2.1. Microspheres
6.2.2.2. Particles (PVA Particles and Gelfoam Particles)
6.2.2.3. Drug-Eluting Beads (DEBs)
6.3. Tumor Ablation
6.3.1. Tumor Ablation Devices/Generators
6.3.2. Consumables & Accessories

7. Interventional Oncology Market, by Application
7.1. Introduction
7.2. Liver Cancer
7.3. Lung Cancer
7.4. Breast Cancer
7.5. Prostate Cancer
7.6. Kidney Cancer
7.7. Bone Metastasis
7.8. Other Cancers

8. Interventional Oncology Market, by End User
8.1. Introduction
8.2. Hospitals
8.3. Ambulatory Surgery Centres
8.4. Research and Academia

Purchase Interventional Oncology Market Report at: https://www.meticulousresearch.com/buy_now.php?pformat=250&vformat=742

9. Interventional Oncology Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific
9.5. Rest of World
9.5.1. Latin America
9.5.2. Middle East & Africa

10. Competitive Landscape
10.1. Growth Strategies
10.2. Competitive Benchmarking
10.3. Market Share Analysis (2018)

11. Company Profiles(Business Overview, Financial Overview, Product Portfolio, Strategic Developments)
11.1. Boston Scientific Corporation
11.2. Cook Medical LLC (A Subsidiary of Cook Group)
11.3. Merit Medical Systems, Inc.
11.4. C. R. Bard, Inc. (A Subsidiary of Becton Dickinson & Company)
11.5. Profound Medical Corp.
11.6. AngioDynamics, Inc.
11.7. BTG plc
11.8. Terumo Corporation
11.9. Medtronic plc
11.10. Healthtronics, Inc.
11.11. EDAP TMS S.A.
11.12. Neuwave Medical, Inc. (Subsidiary of Ethicon Inc.)
11.13. Sirtex Medical Limited
11.14. Trod Medical
11.15. Teleflex Incorporated
11.16. IMBiotechnologies Ltd.

12. Appendix
12.1. Questionnaire
12.2. Available Customization

For Better Understanding Go Through Sample Report Before Buying (Higher Preference For Corporate email ID User): https://www.meticulousresearch.com/request-sample-report/cp_id=4951

Contact Info:
Name: Khushal
Email: Send Email
Organization: Meticulous Research®
Address: Pune, India
Phone: +91 744-7780008
Website: https://www.meticulousresearch.com/product/Interventional-Oncology-Market-4951/

Source URL: https://marketersmedia.com/global-interventional-oncology-market-will-reach-1-51-billion-by-2025-meticulous-research/88942750

Source: MarketersMedia

Release ID: 88942750

More News

Soleimani, a general who became Iran icon by targeting US

Jan 21, 2020

TEHRAN, Iran — For Iranians whose icons since the Islamic Revolution have been stern-faced clergy, Maj. Gen. Qassem Soleimani widely represented a figure of national resilience in the face of four decades of U.S. pressure. For the U.S. and Israel, he was a shadowy figure in command of Iran's proxy forces, responsible for fighters in Syria backing President Bashar Assad and for the deaths of American troops in Iraq. Solemani survived the horror of Iran’s long war in the 1980s with Iraq to take control of the Revolutionary Guard’s elite Quds Force, responsible for the Islamic Republic’s foreign campaigns. Relatively...

Streep, Miranda and Stone are named as Met Gala co-0chairs

Jan 21, 2020

NEW YORK — Next year's Met Gala may be the closest we'll ever come to getting a Miranda Priestly moment at the starry event. Meryl Streep has been named as a co-chair of the Metropolitan Museum of Art's Costume Institute. The Oscar-winner played Priestly, a thinly veiled fictional version of Vogue editor Anna Wintour, in the movie "The Devil Wears Prada." Wintour clearly has no hard feelings because she selected Streep as a co-chair along with Lin-Manuel Miranda and fellow Oscar-winner Emma Stone. Designer Nicolas Ghesquiere rounds out the group. The gala's theme is "About Time: Fashion and Duration," which...

New Sept. 11 exhibit stages the hunt for Osama bin Laden

Jan 21, 2020

NEW YORK — Declassified U.S. government documents and artifacts will be part of a new exhibit about the decade-long search for Osama bin Laden at the site of the New York terrorist attack he masterminded. "Revealed: The Hunt for Bin Laden" opens Nov. 15 at the National September 11 Memorial & Museum, a multimedia account of the mission that ended with bin Laden's death in Pakistan in 2011. With direct access to the operatives who led America's feverish post-9/11 hunt for the top terrorist, the exhibit presents a sort of whodunit drama with graphics, videos and the voices of the...

Queen Latifah to receive Harvard black culture award

Jan 21, 2020

CAMBRIDGE, Mass. — Music artist and actress Queen Latifah is among the honorees being recognized by Harvard University for their contributions to black history and culture. Harvard is set to award the W.E.B. Du Bois Medal to Queen Latifah and six other recipients on Tuesday, according to the Cambridge, Massachusetts, school's Hutchins Center for African and African American Research. Other honorees include poet and educator Elizabeth Alexander, Secretary of the Smithsonian Institution Lonnie Bunch III, poet Rita Dove, co-founder of Black Entertainment Television Sheila Johnson, artist Kerry James Marshall and Robert Smith, founder, chairman and chief executive of Vista Equity...

The Latest: Japan's emperor proclaims ascension to throne

Jan 21, 2020

TOKYO — The Latest on Japanese Emperor Naruhito's enthronement ceremony (all times local): 1:20 p.m. Japan's Emperor Naruhito has proclaimed his ascension to the Chrysanthemum Throne at a palace ceremony. Tuesday's enthronement ceremony is the high point of succession rituals and confirms his succession in May after his father Akihito abdicated. Naruhito is the 126th emperor in the world's oldest hereditary monarchy that historians say dates back 1,500 years. The ceremony serves to showcase the monarchy to win public support and to preserve Japan's cultural heritage. It's also an occasion for diplomacy. Some 2,000 guests, including foreign dignitaries, were invited...

To travel is to live. Unearth your next travel destination here with The Travel Trooper. We love what we do and looking forward to more #travelsquad joining us in this journey.

Contact us: sales@thetraveltrooper.com